ARROWHEAD PHARMACEUTICALS, INC.
In the published model solve dated 2026-Q2, anchored at $86.86, ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is priced for today's economics sustained for ~19.2 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Arrowhead now has an approved drug of its own: REDEMPLO cleared the FDA on November 18, 2025 for familial chylomicronemia syndrome, priced at 45,000 dollars a year, with more than 400 prescriptions received or in process by early May [Source: Arrowhead fiscal 2026 second quarter results, May 8, 2026]. • The revenue line is a partner schedule rather than a business: the Sarepta collaboration accounts for roughly 84% of it, and quarterly revenue fell to 73.7 million dollars in the March 2026 qua
Is ARWR overvalued? See what's priced in →
419 institutional managers reported holding ARWR in 13F filings for the quarter ended 2026-03-31. Together they hold about 84% of the company; the top 10 hold 51%. 90 opened new positions that quarter. Held by BlackRock, Vanguard Group, FMR (Fidelity), among others. On the short side, 11.7M shares were sold short as of the 2026-06-15 count, about 8% of shares outstanding (8.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ARWR's share count grew 36.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ARWR over the trailing three years: 2024: 3 buys totaling $83k. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ARWR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-08 | -13.1% | -6.8% |
| 2023-11-30 | -26.7% | +51.8% |
| 2024-02-07 | -1.2% | -19.8% |
| 2024-05-10 | -12.4% | +27.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ARWR's latest 8-K filings: 2026-08-04 (items 2.02, 9.01); 2026-06-16 (items 5.02, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-03-20 (items 5.07, 9.01); 2026-02-05 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.